Memic has set out to transform robotic-assisted surgery, with proprietary technology that has the potential to far surpass today’s best solutions. Providing unprecedented access and maneuverability, our Memic’s Hominis® surgical platform features miniature, humanoid-shaped robotic arms with human dexterity, superhuman flexibility, and 360˚ articulation. In addition to these features, the system will be sold at a significantly lower price compared to other marketed robotic surgery systems potentially allowing more medical facilities including hospitals and ambulatory surgical centers to access and adopt surgical robotics. Beyond the current applications for transvaginal procedures, Memic is further developing this technology to explore use in abdominal single and multi-port surgery, as well as other transluminal indications.

  • Dvir Cohen Chief Executive Officer

    Dvir Cohen has served as our Chief Executive Officer since October 2013.
    Mr. Cohen has been a leader in the Company from its inception and brings more than 15 years of experience in innovative robotic systems. Mr. Cohen previously was an awarded officer in the Israeli Ministry of Defense specializing in robotic systems for various applications. Mr. Cohen held the positions of research and development manager and robotic project specialist in an elite technology unit of the Israel Intelligence Force (81) and led several opto-mechanical disruptive solutions in the Ministry of Defense, one of which won the Israel Defense Award. Mr. Cohen’s recent recognitions include receiving the Deal of the Year Award from BioFlorida, a life sciences industry association, for Memic’s $96 million Series D financing and being named an Endeavor Entrepreneur by Endeavor Miami, an affiliate of the global Endeavor organization leading the global high-impact entrepreneurship movement. Mr. Cohen earned an MBA from the Recanati Business School at Tel Aviv University, majoring in Business Strategy and Entrepreneurship. He also earned a Bachelor of Science and a Master of Science degree in mechanical engineering from the Technion as part of the “Brakim” excellence program.

    Noam Atar Chief Financial Officer

    Noam Atar has served as our Chief Financial Officer since January 2020.
    Mr. Atar brings more than 20 years of experience as a finance and operations executive with a strong track record formulating and executing strategic initiatives across business operations and changing management, conceptualizing and leading on multi-functional process and performance transformations, generating consensus through collaboration and organizational alignment, and introducing innovation to achieve financial and business goals. Prior to joining the Company, Mr. Atar served as Senior Director of Finance & Supply Chain at Ferring Pharmaceuticals where he led company-wide strategic and operational initiatives. Mr. Atar’s prior experience also includes serving as controller of Bio Technology General Ltd and as the controller of international operations of Radware (RDWR). Prior to that, he served as a senior auditor at PWC. Mr. Atar was also the co-founder & CEO of Rway Applications. Mr. Atar is a certified public accountant and holds a Bachelor of Accounting and Economics degree from the Hebrew University and an MBA from the Recanati Business School at Tel Aviv University. In addition, Mr. Atar is certified in business analytics by Harvard Business School Online.

    Duncan Moffat Executive Vice President, Corporate Operations

    Duncan Moffat is the Executive Vice President of Corporate Operations.
    Mr. Moffat has more than 35 years of experience in senior leadership roles in operations for medical device companies. Previously, he was Senior Vice President of Operations at MAKO Surgical Corp. and a key member of the management team that built the company and led it through the $1.7 billion acquisition by Stryker Corporation in 2013. Mr. Moffat has also held various roles at Philips Healthcare, most recently as Vice President and General Manager of Operations. He earned a Bachelor of Science degree in electrical and electronic engineering from the University of Strathclyde in Glasgow, Scotland.

    Steven Nunes Executive Vice President, Corporate Development and Strategy

    Steven Nunes is the Executive Vice President of Corporate Development and Strategy.
    Mr. Nunes previously served as the Company’s Chief Commercial Officer and built a scalable commercial infrastructure and high performing team before becoming Executive Vice President of Corporate Development and Strategy. He is a highly accomplished senior executive with more than 35 years of experience leading the commercialization of innovative technologies for less invasive surgery. He has a career record of success in medical device startup companies, turnaround situations, and market expansion with large market-leading companies. Mr. Nunes was a founding member and Senior Vice President of Sales and Marketing at MAKO Surgical Corp., where he was part of a team that led unusually strong revenue growth, taking the company from inception to more than $85 million in revenue in four years. MAKO’s success in the orthopedic joint replacement market led to its acquisition by Stryker for $1.7 billion. Prior to MAKO, Mr. Nunes was retained as a senior sales and marketing executive by GE Healthcare following its acquisition of Visualization Technology, Inc. (VTI), an early market leader in the development and sales of electromagnetic based image guided surgery systems. Mr. Nunes was responsible for the commercialization of VTI’s products from inception, established VTI’s products as standard of care in the market and led the integration of VTI’s commercial organization into GE Healthcare. Mr. Nunes also previously served as a distributor for Richard Wolf Medical Instruments, a pioneer in products for laparoscopic surgery and a market leader and innovator in gynecologic surgery. Mr. Nunes earned a Bachelor of Arts degree in communications from the University of Massachusetts Amherst.

    Dalia Argaman Senior Vice President, QA & RA

    Dalia Argaman is responsible for our Quality Assurance and Regulatory Affairs.
    Ms. Argaman is a seasoned leader with more than 25 years of experience in quality assurance, regulatory affairs and clinical research, previously serving as Vice President of Clinical, Regulatory Affairs and QA for EarlySense before joining the Company. Ms. Argaman has led the submission of more than 12 successful FDA applications (510K and PMA), prepared more than 10 CE applications, established company quality systems in compliance with ISO13485 and FDA Quality System Regulations (QSR), successfully led submissions to Australia, Taiwan, Singapore, Japan and China, and led all verification and validation testing required for regulatory submissions. Ms. Argaman holds a Bachelor of Science degree in chemistry from Faculty of Exact Sciences and a Master of Science focused on chemical physics from Tel-Aviv University.

    Hagai Berkovich Chief Operations Officer

    Hagai Berkovich has served as our Chief Operations Officer since October 2018.
    Mr. Berkovich has more than 24 years of executive, leadership and management experience in operations. Before joining the Company, Mr. Berkovich served as Supply Chain Director at Check-Cap, a medical device company developing the world’s first ingestible imaging capsule system for colorectal cancer screening. His previous experience includes serving as COO at Motorika, a robotic company for rehabilitation solutions, and as Operations VP and CEO at Tamuz F.T.K Solutions, where he led the scale up activities with respect to the Mazor robotic system. His other roles have included Operations, Airborne Structure Director at Elbit Systems – Cyclone and Business Unit Vice President at Sanmina SCI – Israel Medical Systems. Mr. Berkovich holds an MBA from the Recanati Business School at Tel Aviv University and a Bachelor of Science degree in aeronautical engineering from the Technion.

    Stavit Cohen Senior Vice President, R&D

    Stavit Cohen leads the Company’s Research and Development.
    Ms. Cohen brings deep experience in leading R&D at a senior leadership level at companies with advanced medical technologies. Ms. Cohen has a proven track record in driving innovation and creating the backbone of a top-notch R&D organization with the use of best-in-class practices and methodologies. Previously, she served as Senior Director of R&D and Site Leader at EPD Solutions, a Philips company where she played key roles in delivering an innovative strategic roadmap, technology adoption, and partnerships with Medtronic, Inc. Before that, Ms. Cohen held various roles at Abbott Laboratories, most recently serving as R&D Leader, Site Leader and Chief Executive Officer of MediGuide, Inc. (acquired by St. Jude Medical, Inc. in 2008, which was subsequently acquired by Abbott in 2017). Ms. Cohen earned an MBA and a Bachelor of Science degree in computer science from Technion – Israel Institute of Technology.

    Dr. Michael Conditt Senior Vice President, Strategic Marketing & Clinical Development

    Dr. Michael Conditt leads product management, clinical development and post-market clinical research at the Company.
    Dr. Conditt has 25 years of experience in innovative medical devices, sensors, robotics, biomechanics, and clinical research at medical device startup companies. Prior to joining the Company, Dr. Conditt was VP of Clinical Development at OrthoSensor (acquired by Stryker in 2021), a company developing and commercializing intelligent orthopedic devices and data services that provide quantitative feedback to surgeons and hospitals. Prior to OrthoSensor, Dr. Conditt established a multi-faceted, comprehensive clinical research program at MAKO Surgical Corp. At MAKO, he worked with key opinion leaders to establish the clinical and economic value of less invasive, more accurate robotic-assisted surgery. Following the company’s acquisition by Stryker for $1.7 billion, he helped lead the integration of robotics into Stryker’s portfolio. Dr. Conditt also developed the clinical strategy at Surgical Theater, providing guidance for the application of augmented reality technology for neurosurgery. Dr. Conditt has authored more than 75 peer-reviewed manuscripts and received numerous academic honors and awards for his research. He earned a PhD degree in biomedical engineering from Northwestern University, where he built a haptic robot to study human motor control, a Master of Science degree in bioengineering from the University of Pennsylvania and a Bachelor of Science degree in mechanical engineering from Texas Tech University.

    Thomas Klug Senior Vice President, Customer Services & US Operations

    Thomas Klug brings more than 30 years of medical device customer service and operations experience to the Company.
    Mr. Klug spent 10 years of his career building Customer Service Organizations at start-up medical device companies. Prior to joining the Company, he served as Vice President, Global Customer Care at Synaptive Medical, an innovative Toronto-based company revolutionizing surgical visualization and patient imaging. Before that, he was Vice President of Global Customer Support at MAKO Surgical Corp. where his team supported the rapid growth and success of the start-up orthopedics robotics company that was ultimately acquired by Stryker for $1.7 billion. With more than 17 years in Carl Zeiss’ medical device division, Mr. Klug had roles of increasing responsibilities and completed his time with them as Director of Field Services where he was responsible for installation, service and maintenance of opto-electronic diagnostic and surgical instrumentation including surgical laser systems. Mr. Klug earned a degree in electronic engineering from Cayuga College and a Certificate in International Business Management from Georgetown University.

    Ariela Levi Senior Vice President, People

    Ms. Levi is responsible for overseeing the company’s human resource initiatives.
    Ms. Levi is a seasoned HR leader with experience in talent acquisition, organization design and development, and HR business partnering. Her areas of expertise also include building a culture of engagement and high performance and steering global organizations through growth and transformation. She is passionate about people, building forward-thinking teams, and providing valuable interactions. Before joining Memic, she served as Vice President of HR for NICE Actimize. She has a Bachelor of Science degree in psychology and management from Tel Aviv University.

    Chad Zaring Chief Commercial Officer

    Chad Zaring leads the Company’s commercialization efforts.
    Mr. Zaring has nearly 20 years of industry experience with proven success in driving commercial results at innovative robotic surgery companies including Intuitive Surgical and Mazor Robotics (acquired by Medtronic plc in 2018). In his most recent position as Chief Commercial Officer at Venus Concept Inc., Mr. Zaring was responsible for global sales, marketing and training strategy and robotics R&D. Mr. Zaring also previously served as District Manager at Ethicon Endo-Surgery, a subsidiary of Johnson & Johnson, and as a urology sales representative at Merck and Co., Inc. Mr. Zaring earned a Bachelor of Arts degree in biology from Juniata College in Pennsylvania.

  • Maurice Ferre Chairman of the Board

    Maurice R. Ferré MD is INSIGHTEC’S CEO and chairman of the board of directors. He brings over 20 years of experience in the medical device industry. Before INSIGHTEC, Dr. Ferré served as chairman of the board and CEO of MAKO Surgical Corp., a transformational robotic surgical company that he co-founded in 2004. The company was IPO’d in 2008 and sold to Stryker Corp. for $1.65 billion in 2013. Prior to MAKO, Dr. Ferré was founder, CEO, and president of Visualization Technology, Inc., which became the world leader in image-guided surgery for ENT, cranial, and orthopedic procedures. The company was acquired by GE Healthcare in 2002.
    Dr. Ferré earned his Doctor of Medicine and Master of Public Health degrees from Boston University. He received the prestigious Ernest & Young 2007 Entrepreneur of the Year Award. He is currently active on the boards of Advamed, the Everglades Foundation, and Boston University.

    About INSIGHTEC: the company’s MR-guided focused ultrasound technology allows to perform procedures with surgical precision but without incisions, thus transforming the standard of care. The company’s non-invasive Exablate and Exablate Neuro platforms are clinically proven for treating essential tremor, painful bone metastases, and uterine fibroids. INSIGHTEC continuously invests in and expanding its current and investigational applications.

    Eyal Lifschitz Chairman of Board's Business Committee

    Eyal Lifschitz is CEO, general partner, and co-founder of Peregrine Ventures.
    Prior to founding Peregrine, Eyal co-founded and led the business development efforts of multiple medical technology companies, including PharmaSys (acquired by Elan Corp. NYSE:ELN), ECR (acquired by AVX Corp. NYSE:AVX), Visioncare Ophthalmic Technologies, and BioControl Ltd. From 2003-2007, Eyal also served as a director of Given Imaging (NASDAQ: GIVN).

    Peregrine is an Israeli venture capital fund, with a focus on medical devices and an impressive record of founding, managing, and promoting Israeli hi-tech companies. Peregrine enjoys a wide network of contacts, and is supported by a investment committee and advisory board consisting of expert teams specializing in all applicable disciplines. The fund has invested in and initiated some of Israel’s leading medical companies, including Neovasc, B-Balloon, Valtech, Eximo, Memic, and Cordio.

    Lior Shahory Board Member

    Lior brings extensive experience in investment due diligence, strategic planning, project management, and business development. He works closely with entrepreneurs to establish successful companies.
    Lior serves as CEO of Incentive, Peregrine’s technology incubator. Under his leadership, Incentive has received seven excellence awards from the State of Israel.
    Prior to Peregrine, Lior served as deputy director of the Israel Chief Scientist’s incubator program.
    Lior holds a BA in economics and business management from the University of Haifa, and an MBA from Tel Aviv University.

    Dr. Irit Yaniv M.D., MBA Board Member

    Dr. Irit Yaniv is a seasoned medtech executive, and has held CEO positions at medical device companies Impulse Dynamics and MetaCure.
    Dr. Yaniv plays a key role in leading Accelmed’s early-stage portfolio companies, serving either as chairperson or as an active board member.
    Dr. Yaniv holds an MD degree from Ben Gurion University, and an MBA from the Recanati Business School at Tel Aviv University.

    Accelmed is an investment firm focused on creating value for medical device companies and technologies. Founded by Mori Arkin and Uri Geiger. It invests in small and mid-cap private and public companies. A successful advocate of the platform model with a proven track record, Accelmed boasts a large team of accomplished investment professionals. Its vision is to create leading med-tech players by merging commercial platforms with small innovative growth companies, predominantly from Israel.

    Dr. Israel Frieder Board Member

    Dr. Israel Frieder serves Ltd., as chairman at AA Pearl Investments, Ltd., as chairman at ETV Energy, Ltd., and as chairman at Ariel Scientific Innovations Ltd.
    He has served on the board of directors at RR Media, at Cellvine Ltd., and at RiT Technologies Ltd.
    He received his graduate degree from the Technion, an MBA from the Hebrew University of Jerusalem, and a doctorate degree from Bar-Ilan University.

    Dr. Morry Blumenfeld Board Observer

    Dr. Morry Blumenfeld is president and CEO of medical device consulting company Quescon Consultants, Ltd., and a partner at Meditech Advisors, LLC. He was an executive at GE for nearly 35 years, and served GE Medical Systems Business in numerous roles, including initiating both the CT and MRI businesses, and as managing director of GE Medical Systems in Israel.
    Morry holds five patents, and serves or has served on the boards of a number of medical device and technology companies in the USA and Israel – as well as numerous Canadian, international, and Israeli advisory boards in technology and science. He is on the board of the Hebrew University and Yissum (the Hebrew University’s tech transfer company), and on the scientific advisory board of the Momentum Fund of Ramot (Tel Aviv University’s tech transfer company).
    Dr. Blumenfeld received his undergraduate degree and Ph.D from the University of Toronto.

    Guy ShamirBoard Observer

    Mr. Guy Shamir has served as business development manager at Mivtach Shamir Holdings, Ltd. since 2011.
    He previously served as a director at Tefron, Ltd., and as a director at Manif Financial Services, Ltd.
    He holds a degree in business administration from the Interdisciplinary Center in Herzliya.

    Mivtach Shamir Holdings is an investment company based in Israel, led by Israeli investor Meir Shamir. Mivtach Shamir invests in three sectors: technology and communications, industrial investments, and real estate. Shares of Mivtach Shamir are traded on the Tel Aviv Stock Exchange (TASE: MISH).

    Mark “ Goldie “ Goldwasser Board Member

    Mark Goldwasser has worked in Finance based in Wall St for over 40 years Mark has worked at a variety of Investment Banks including Bear Stearns, Lazard Freres, Jefferies, and ING Barings in leading roles, many as a Managing Director or Executive Vice President.
    Mark was responsible for building National Securities into one of the fastest-growing Independent Broker-Dealers and Investment Bank. Mark was CEO of National for 16 years and Executive Chairman of National Holdings Corporation a Public Co for over 10 years. As Chairman he was responsible for the acquisition of two other publicly traded financial service companies.
    At National Mark was the Co-Founder of Robotic Ventures the countries first VC fund investing in Robotics. One company was iRobot which went public and Z Cat which evolved into Mako Surgical.
    Over his long career, Mark has been responsible for raising tens of Billions of dollars in a variety of securities and markets including emerging markets, SPV s for Unicorns, Fixed Income and Private Venture Equity including Israel.
    Mark is currently the CEO of Ceros Financial Services with over $ 7 Billion in Assets.

back to top
think nimble

think nimble

think boundless

think boundless

clinical spectrum
think forward

think forward

news & events
think together

think together

contact us